Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

REGN

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:REGN
DateTimeSourceHeadlineSymbolCompany
27/06/201904:30Dow Jones NewsFDA Approves Sanofi, Regeneron Treatment for Chronic Rhinosinusitis with Nasal PolyposisNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/06/201903:30PR Newswire (US)FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposisNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/06/201903:29PR Newswire (US)FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal PolyposisNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/06/201920:39Dow Jones NewsRegeneron, Sanofi Report Positive Topline Phase 2 Asthma ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
21/06/201914:59PR Newswire (US)Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in AsthmaNASDAQ:REGNRegeneron Pharmaceuticals Inc
20/06/201907:21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/06/201921:56Dow Jones NewsRegeneron Says Early-Stage Results Positive for REGN1979 in LymphomaNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/06/201921:00PR Newswire (US)Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymp...NASDAQ:REGNRegeneron Pharmaceuticals Inc
30/05/201906:19Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
23/05/201923:30PR Newswire (US)Regeneron Announces Upcoming Investor Conference PresentationNASDAQ:REGNRegeneron Pharmaceuticals Inc
16/05/201921:00PR Newswire (US)Updated Libtayo® (cemiplimab-rwlc) Results Reinforce Durable and Substantial Response Rates in Advanced Cutaneous Squamous C...NASDAQ:REGNRegeneron Pharmaceuticals Inc
16/05/201906:05Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REGNRegeneron Pharmaceuticals Inc
15/05/201900:47Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:REGNRegeneron Pharmaceuticals Inc
14/05/201906:19PR Newswire (US)FDA Approves EYLEA® (aflibercept) Injection for Diabetic RetinopathyNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/05/201905:29Dow Jones NewsRegeneron Says FDA Approves Eylea Injection for All Diabetic Retinopathy TreatmentNASDAQ:REGNRegeneron Pharmaceuticals Inc
14/05/201904:45PR Newswire (US)FDA Approves EYLEA® (aflibercept) Injection for Diabetic RetinopathyNASDAQ:REGNRegeneron Pharmaceuticals Inc
10/05/201906:52Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/05/201907:01Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
08/05/201904:06Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:REGNRegeneron Pharmaceuticals Inc
07/05/201923:39Dow Jones NewsEU Approves Sanofi and Regeneron's Dupixent for Severe AsthmaNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/05/201922:59PR Newswire (US)Dupixent® (dupilumab) Approved for Severe Asthma by European CommissionNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/05/201921:51Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:REGNRegeneron Pharmaceuticals Inc
07/05/201921:36Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
07/05/201921:13Dow Jones NewsRegeneron's Expense Growth Weighs on Operating IncomeNASDAQ:REGNRegeneron Pharmaceuticals Inc
07/05/201920:30PR Newswire (US)Regeneron Reports First Quarter 2019 Financial and Operating ResultsNASDAQ:REGNRegeneron Pharmaceuticals Inc
04/05/201906:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REGNRegeneron Pharmaceuticals Inc
30/04/201906:01PR Newswire (US)Regeneron Announces Upcoming Investor Conference PresentationsNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/04/201910:29Dow Jones NewsFDA Approves Expanded Label for PraluentNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/04/201909:19PR Newswire (US)FDA Approves Praluent® (alirocumab) to Prevent Heart Attack, Stroke and Unstable Angina Requiring HospitalizationNASDAQ:REGNRegeneron Pharmaceuticals Inc
27/04/201906:20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:REGNRegeneron Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:REGN